Thought Leadership
FDA Announces Major Generic Drug Labeling Changes In the Wake of Preemption Decisions Involving Generic Drug Product Liability
November 21, 2013
Chad Landmon
Corporate Compliance Insights

Axinn partner Chad Landmon co-authored, "FDA Announces Major Generic Drug Labeling Changes In the Wake of Preemption Decisions Involving Generic Drug Product Liability," which was featured in the Novmeber 21, 2013 edition of Corporate Compliance Insights.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.